Navigation Links
Axia Group (AGIJ:PK) Reaches Agreement for Development and Marketing of Psoriasis Products
Date:8/11/2011

OTTAWA, Ontario, Aug. 11, 2011 /PRNewswire/ -- Axia Group (Pink Sheets: AGIJ, http://www.axiacorporation.com/) Collagenna Skin Care Products announced that is has reached an agreement with Prime Pharma, a subsidiary of the TSE publicly traded company Allegiance Equity Corporation (TSXV: ANQ.V) www.allegianceequity.com for the marketing and development of Mahonia Products which have been clinically proven to help relieve the symptoms related to psoriasis.

Prime Pharma's premier product is the Relieva cream, an over the counter psoriasis cream which has been reformulated into a more effective product. The agreement is based upon a joint venture for worldwide, non-internet marketing sales of the Mahonia extract product line, both present and future products.

Company agreement will allow Collagenna access to worldwide patents as well as new patentable technology. With Mahonia as a proven active ingredient, Prime Pharma possesses a patented extract with which the company plans to find innovative ways to help distinguish the company from the competition.

Collagenna plans to commence clinical trials to validate the preliminary testing, and hopes to publish results in the next 30 days.

The company commenced the necessary regulatory paperwork which will allow Collagenna to market Relieva in both Canada and the US. Company expects this process to take around 60 days. In the meantime we will initiate marketing efforts immediately.

An Independent report (Research and Markets) of 2004 on world-wide psoriasis prescription market concluded this market to grow at compound annual rate of 23.6% to over $3.1B worldwide by 2009. According to Global Industry Analysts Inc., Global psoriasis drugs market will exceed $ 7.3 billion dollars by 2015.

Collagenna Skin Care Products specializes in Anti-aging products with an emphasis on Collagen stimulation both topically and internally. The company sells its products mainly through its specialized skin care clinics through its ever expanding network of distribution partners.

More details and updates will be provided shortly and on a timely basis.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Axia Group Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Axia Group Inc. cautions you that any forward-looking information provided by or on behalf of Axia Group Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Axia Group Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Axia Group Inc.'s control. In addition to those discussed in Axia Group Inc.'s press releases, public filings, and statements by Axia Group Inc.'s management, including, but not limited to, Axia Group Inc.'s estimate of the sufficiency of its existing capital resources, Axia Group Inc.'s ability to raise additional capital to fund future operations, Axia Group Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Axia Group Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Axia Group Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

corporate@axiacorporation.com


'/>"/>
SOURCE Axia Group Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuse Science Partners With the New England Consulting Group to Advance Technology Licensing Efforts in Pharmaceutical and OTC Categories
2. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results
3. Systech Selects Vantage Consulting Group as their Sales Agent in Puerto Rico
4. Global Pharm Holdings Group Completes Acquisition of Pacific Asia Pharm Investment Group Co., Ltd.
5. Winner Medical Group Inc. to Host Third Quarter 2011 Earning Conference Call on Wednesday, August 10, 2011 at 8:30 a.m. EDT
6. Foundation Venture Capital Group Investment Shows Promise in Diagnosis of Alzheimers Disease Using a Drop of Blood
7. Hanger Orthopedic Group Announces Five Acquisitions Producing $20.2 million of Annual Net Revenue
8. Vantage Health South African Subsidiary Negotiates Supply Agreement With Major South African Retail Group
9. Groupe Athena, Inc. Profits Soar on Record Revenues
10. Hanger Orthopedic Group Celebrates Its 150th Anniversary: Celebrations to Commence with NYSE Bell Ringing on August 10
11. Simcere Pharmaceutical Group to Announce Second Quarter 2011 Financial Results on Tuesday, August 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):